Celldex Therapeutics, Inc.
CLDXHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeCelldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. Valued at $2.77B, CLDX is a mid-cap name in its sector. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.
Market Cap
$2.77B
Beta
0.90
P/E (TTM)
—
P/E (Fwd)
-7.86
EPS (TTM)
$-4.26
EPS (Fwd)
$-4.50
ROE
-48.9%
ROA
-30.9%
Cash
$451.5M
Total Debt
$1.9M
Free CF
-$126.3M
52W Change
57.7%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $451.5M in cash comfortably exceeding the $1.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$126.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -48.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $2.4M to $1.5M.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Celldex Therapeutics, Inc.'s trajectory.